<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822692</url>
  </required_header>
  <id_info>
    <org_study_id>FWH20080055H</org_study_id>
    <nct_id>NCT00822692</nct_id>
  </id_info>
  <brief_title>Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection</brief_title>
  <official_title>Prospective Randomized Double Blind, Placebo-Controlled Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection on 30 Day Recurrence Rates.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wilford Hall Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Air Force Office of the Surgeon General</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emergency Medicine Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wilford Hall Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be enrolled in a multi-center study (Wilford Hall Medical Center and Brooke
      Army Medical Center) to prospectively evaluate outcome after treatment for an uncomplicated
      skin abscess.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will receive incision and drainage and wound cultures. Patients will then be
      randomized to 1) septa double strength two pills orally twice a day x 7 days or 2)placebo.
      Patients will then return to the emergency room on days 3 and 7 for wound repacking and
      evaluation. The primary outcome recurrence rates within 30 days of treatment. Patients who
      are not improving at the following visit will then be treated with additional antibiotics if
      needed. Data will be analyzed both by initial randomization and intention to treat.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence Rates of Abscesses</measure>
    <time_frame>30 days after incision and drainage</time_frame>
    <description>Number of patient with a new abscess in same or different location as previous lesion</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Abscess</condition>
  <condition>Methicillin-Resistant Staphylococcus Aureus Infection</condition>
  <arm_group>
    <arm_group_label>Bactrim DS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trim/sulfa (800/160) two tablets orally (PO) twice a day (BID) x 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>matched placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matched placebo 2 pills orally (PO) twice a day (BID) x 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trim/ Sulfa DS</intervention_name>
    <description>bactrim DS (800/160) two tablets PO BID x 7 days</description>
    <arm_group_label>Bactrim DS</arm_group_label>
    <other_name>Bactrim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matched placebo 2 pills PO BID x 7 days</description>
    <arm_group_label>matched placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients age 18-65 who present to the emergency department with a skin abscess
             that requires incision and drainage.

        Exclusion Criteria:

          -  Patients with diabetes, HIV, cancer or other immunocompromised patients.

          -  Additionally, any patients who received antibiotics within one week of presentation or
             were hospitalized in previous month will be excluded to minimize potential confounding
             variables.

          -  Pregnant and breastfeeding patients will also be excluded due to possible safety
             concerns with antibiotic treatment.

          -  Patients with abscesses on head, face, perirectal, or periananal regions, abscesses
             with known tracks or fistulas to deeper structures, or abscesses requiring surgical
             drainage in an operating room are excluded.

          -  Finally, patients with sulfa allergy will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gillian R Schmitz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wilford Hall Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wilford Hall Medical Center</name>
      <address>
        <city>Lackland AFB</city>
        <state>Texas</state>
        <zip>78236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2009</study_first_posted>
  <results_first_submitted>July 29, 2009</results_first_submitted>
  <results_first_submitted_qc>July 29, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 3, 2009</results_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wilford Hall Medical Center</investigator_affiliation>
    <investigator_full_name>Gillian Schmitz</investigator_full_name>
    <investigator_title>Emergency Physician</investigator_title>
  </responsible_party>
  <keyword>Abscess</keyword>
  <keyword>Cellulitis</keyword>
  <keyword>Antibiotics</keyword>
  <keyword>MRSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Abscess</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methicillin</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled at 3 hospital emergency departments from July 1, 2008 to June 1, 2009.</recruitment_details>
      <pre_assignment_details>Patients were assigned by block randomization and data was analyzed with intention to treat analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bactrim DS (800/160) Two Tablets PO BID x 7 Days</title>
          <description>Active Intervention Arm</description>
        </group>
        <group group_id="P2">
          <title>Matched Placebo 2 Pills PO BID x 7 Days</title>
          <description>Placebo arm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63">July 1, 2008</participants>
                <participants group_id="P2" count="76">July 1, 2008</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46">June 1, 2009</participants>
                <participants group_id="P2" count="51">June 1 , 2009</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bactrim DS (800/160) Two Tablets PO BID x 7 Days</title>
          <description>Active Intervention Arm</description>
        </group>
        <group group_id="B2">
          <title>Matched Placebo 2 Pills PO BID x 7 Days</title>
          <description>Placebo arm</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="139"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.6" spread="13"/>
                    <measurement group_id="B2" value="30.6" spread="13"/>
                    <measurement group_id="B3" value="31.06" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recurrence Rates of Abscesses</title>
        <description>Number of patient with a new abscess in same or different location as previous lesion</description>
        <time_frame>30 days after incision and drainage</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bactrim DS (800/160) Two Tablets PO BID x 7 Days</title>
            <description>Active Intervention Arm</description>
          </group>
          <group group_id="O2">
            <title>Matched Placebo 2 Pills PO BID x 7 Days</title>
            <description>Placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence Rates of Abscesses</title>
          <description>Number of patient with a new abscess in same or different location as previous lesion</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bactrim DS (800/160) Two Tablets PO BID x 7 Days</title>
          <description>bactrim DS (800/160) two tablets PO BID x 7 days</description>
        </group>
        <group group_id="E2">
          <title>Matched Placebo 2 Pills PO BID x 7 Days</title>
          <description>matched placebo 2 pills PO BID x 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>treatment failure</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gillian Schmitz, MD</name_or_title>
      <organization>Wilford Hall Medical Center</organization>
      <phone>919-724-9185</phone>
      <email>gillianmd@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

